Table 1.
Baseline Patient Characteristics.
| Total Patients | PFS <6 months | PFS ≥ 6 months | p-value | |
|---|---|---|---|---|
| Total Number Patients (N) | 43 | 34 | 9 | – |
| Age (years) | ||||
| Mean | 52.58 | 52.71 | 52.11 | 0.9167± |
| Range | (33-71) | (33-71) | (39-62) | |
| Sex | ||||
| Male | 0 (0%) | 0 (0%) | 0 (0%) | – |
| Female | 43 (100%) | 34 (100%) | 9 (100%) | |
| Metastatic disease at diagnosis | 3 (7.14%) | 3 (9.09%) | 0 (0%) | 1.0000* |
| Number of Metastatic Locations | ||||
| 1 | 9 (20.93%) | 6 (17.65%) | 3 (33.33%) | 0.4284* |
| 2 | 12 (27.91%) | 9 (26.47%) | 3 (33.33%) | |
| 3+ | 22 (51.16%) | 19 (55.88%) | 3 (33.33%) | |
| Lines of chemotherapy in metastatic setting | ||||
| Mean | 2.14 | 2.09 | 2.33 | 0.8179± |
| Range | (0-7) | (0-5) | (0-7) | |
| Receptor status | 1.0000* | |||
| HR+/HER2- | 24 (55.81%) | 19 (55.88%) | 5 (55.56%) | |
| HER2+ | 2 (4.65%) | 2 (5.88%) | 0 (0%) | |
| TNBC | 17 (39.53%) | 13 (38.24%) | 4 (44.44%) | |
| Treatment | ||||
| PD-L1/PD-1 | 12 (27.91%) | 11 (32.35%) | 1 (11.11%) | 0.0015* |
| IO + Chemotherapy | 12 (27.91%) | 5 (14.71%) | 7 (77.78%) | |
| Other IO, No Chemo | 19 (44.19%) | 18 (52.94%) | 1 (11.11%) | |
| ECOG PS | ||||
| 0 | 23 (53.49%) | 18 (52.94%) | 5 (55.56%) | – |
| 1 | 20 (46.51%) | 16 (47.06%) | 4 (44.44%) | |
| Radiation within 30 days of IO | 3 (6.98%) | 1 (2.94%) | 2 (22.22%) | 0.1060* |
| Lymphocyte count (k/uL) | ||||
| Mean (SD) | 1.23 (0.68) | 1.13 (0.47) | 1.59 (1.14) | 0.2948± |
| Alkaline Phosphatase (U/L) | ||||
| Mean (SD) | 99.72 (56.82) | 105.5 (62.42) | 77.89 (14.18) | 0.1389± |
| LDH (U/L) | ||||
| Mean (SD) | 449.71 (787.83) | 500.22 (863.14) | 217.4 (99.02) | 0.6313± |
*Fisher Exact Test.
±Wilcoxon rank-sun Test.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; SD, Standard Deviation.